Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • NPPA fixes prices of...

    NPPA fixes prices of 58 formulations, details

    Written by Ruby Khatun Khatun Published On 2018-07-05T13:55:58+05:30  |  Updated On 5 July 2018 1:55 PM IST
    NPPA fixes prices of 58 formulations, details

    New Delhi: Through a recent notification, Government of India, Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals and National Pharmaceutical Pricing Authority (NPPA) has fixed/revised ceiling prices/retail prices of 58 formulations exclusive of goods and services tax (GST).


    While NPPA has fixed retail prices of 56 formulations, it has also capped the ceiling prices of two formulations.

    The prices have been fixed/revised under the Drug (Prices Control) Order, 2013, it added.

    These include a number of life-saving combinations of anti-hypertensives, anti-diabetics, lipid-lowering agents, antibiotics, diuretics, antimalarial drugs and haemotanics like Rosuvastatin +Clopidogrel Capsule (Crevast CV 20), Amoxycillin +Clavulante Dry Syrup (Clanoxy Forte), Hydroxychloroquine Sulphate Tablet (OXCQ 300mg), Telmisartan + Chlorthalidone Tablet (Telpha-CH), Brimonidine + Timolol Eye Drops (New Albrim LST), Ferrous Ascorbate +Folic Acid Tablet, Cefixime + Ofloxacin Tablet (Ranixime Plus), Furosemide, etc.


    The NPPA is mandated to fix/revise the prices of controlled bulk drugs and formulations and to enforce prices and availability of the medicines in the country.


    It also monitors the prices of decontrolled drugs in order to keep them at reasonable levels.

    The regulator implements and enforces the provisions of the Drugs (Prices Control) Order.

    It is also entrusted with the task of recovering amounts overcharged by manufacturers for the controlled drugs from the consumers.


    To check out the details click on the links given below


    http://www.nppaindia.nic.in/ceiling/press04July18/FormulationPrices(50).pdf


    http://www.nppaindia.nic.in/ceiling/press04July18/FormulationPrices(6).pdf


    http://www.nppaindia.nic.in/ceiling/press04July18/FormulationPrices(2).pdf


    Medical Dialogues had earlier reported that NPPA has fixed the retail and ceiling prices of 22 formulations used for the treatment of various ailments including HIV, bacterial infections and cardiac conditions among others.


    Read also: NPPA fixes prices of 22 drugs including ORS, Sun pharmas Rosuvas, Details

    ceiling pricesDepartment of PharmaceuticalsfixesGoods and Services TaxGovernment of IndiaGSTMinistry of Chemicals and FertilizersNational Pharmaceutical Pricing AuthorityNPPARetail Prices

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok